Arctic Bioscience AS (OSL:ABS) Short-Term Debt & Capital Lease Obligation : kr31.39 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Arctic Bioscience AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr31.39 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Arctic Bioscience AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr1.47 Mil.

Arctic Bioscience AS Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Arctic Bioscience AS's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS Short-Term Debt & Capital Lease Obligation Chart

Arctic Bioscience AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

2.70

1.27

1.10

3.53

31.39

Arctic Bioscience AS Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial							1.10	-	3.53	-	31.39

Arctic Bioscience AS Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Arctic Bioscience AS Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arctic Bioscience AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

9TD:Germany

Address

Industrivegen 42, Orsta, NOR, 6155

Website

https://www.arctic-bioscience.com

Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. The company is developing a novel, oral drug candidate (HRO350) for the treatment of mild-to-moderate psoriasis. The company operates geographically in Norway, Americas, Europe, and APAC, with majority of the revenue deriving from Europe.

Arctic Bioscience AS Headlines

No Headlines